Supporting Information M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors Yeon Woong Choo, 1,† Mikyung Kang, 2,† Han Young Kim, 1 Jin Han, 1 Seokyung Kang, 1 Ju-Ro Lee, 1 Gun-Jae Jeong, 1 Sung Pil Kwon, 1 Seuk Young Song, 1 Seokhyeong Go, 2 Mungyo Jung, 1 Jihye Hong, 2 Byung-Soo Kim 1,2,3, * 1 School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea 2 Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea 3 Institute of Chemical Processes, Seoul National University, Seoul 08826, Republic of Korea § These authors contributed equally to this work. *Byung-Soo Kim, Ph.D., E-mail: byungskim@snu.ac.kr Key Words: cancer immunotherapy • checkpoint inhibitor • macrophage polarization • nanovesicle • tumor-associated macrophage